

Circulating fibrocytes as a new tool to predict lung cancer progression after surgery?

To the Editor:

Copyright ©The authors 2021. For reproduction rights and permissions contact permissions@ersnet.org

Received: 28 April 2021 Accepted: 7 Sept 2021 Lung cancer remains the leading cause of cancer death. In 2008, 2 206 771 new cases and 1 796 144 deaths were reported worldwide [1]. At diagnosis, approximately one third of the patients have a potentially resectable tumour that is confined to the chest without clinical evidence of mediastinal lymphadenopathy (clinical stages I and II). Nevertheless, even after complete surgical resection, the overall survival in such patients with early-stage disease remains disappointing. The 5-year survival rate even for patients with stage IA or IB non-small cell lung cancer (NSCLC) is 73% and 56%, respectively [2]. Besides, the 5-year risks of local or regional recurrence after surgery alone for NSCLC for stages IA, IB, IIA, IIB and IIIA are also high (16%, 23%, 37%, 39% and 30%, respectively [3]). The 5-year survival of small cell lung cancer (SCLC) patients with early-stage resected disease (T1,2N0M0) is roughly similar, around 50% [4]. Relapse of the disease at distant sites, despite complete removal of all macroscopic lesions, is the main cause of treatment failure [5–8]. The presence of micro-metastatic disease at resection is the likely reason for such relapse. However, the mechanisms involved in micro-metastases propagation remains to be clarified.

Fibrocytes, a distinct population of collagen-producing, monocyte-derived cells, are involved in physiological (wound healing) and pathological processes, such as idiopathic pulmonary fibrosis [9], where circulating fibrocytes are associated with higher mortality [10, 11]. Accumulating evidence suggests that fibrocytes also play a role in the tumour microenvironment. Indeed, it has been shown that circulating fibrocytes could favour the invasion of cancer cells by inducing the influx of Ly-6C⁺ monocytes *via* CCL2 secretion, thus contributing to pre-metastatic conditioning [12]. Moreover, in a recent study conducted in lung cancer samples, a significantly increased number of fibrocytes in bevacizumab-treated tumours suggested that fibrocytes could also mediate acquired resistance to bevacizumab [13]. Thus, the role of fibrocytes in lung cancer physiopathology needs to be investigated.

Our aim was to examine whether circulating and peri-bronchial fibrocytes are associated with disease-free survival (DFS) in lung cancer patients.

We conducted, in a local cohort of patients [14], a *post hoc* analysis of a prospective study among 35 patients who underwent surgical resection for a very early stage lung cancer (stage IA and IB lung cancer, according to the 7th American Joint Committee on Cancer TNM classification). This clinical trial was sponsored by the University Hospital of Bordeaux. The study was registered at ClinicalTrials.gov as NCT01692444 (*i.e.* the "Fibrochir" study). The study protocol was approved by the local research ethics committee on 30 May, 2012, and the French National Agency for Medicines and Health Products Safety on 22 May, 2012. All subjects provided written informed consent. We collected the following patient characteristics: age, gender, smoking habits, lung cancer type, TNM classification. Fragments of the tumour and from distal parenchyma were obtained from lung resection material at a distant of at least 2 cm from the tumour. Fibrocytes were quantified as FSP1 and CD45 double-positive cells in the lamina propria of distal bronchi, as previously described [14]. Moreover, circulating fibrocytes were harvested on the day of the surgery and immediately quantified following blood sampling, from peripheral blood mononuclear cells (PBMCs) separated from the whole blood, and were identified as double positive cells for the surface marker CD45 and the intracellular marker collagen I by flow cytometry [14].



Shareable abstract (@ERSpublications) Fibrocytes could identify patients who will suffer from a worse than expected prognosis after surgery for early lung cancer https://bit.ly/3htPVtC

Cite this article as: Henrot P, Beaufils F, Thumerel M, *et al.* Circulating fibrocytes as a new tool to predict lung cancer progression after surgery? *Eur Respir J* 2021; 58: 2101221 [DOI: 10.1183/ 13993003.01221-2021].

The primary outcome of interest was the disease free survival (DFS) after surgical resection for stage IA and IB lung cancer. Receiver operating characteristic (ROC) curve analysis was performed for circulating fibrocyte concentration and fibrocyte density in distal tissue specimens and in the tumour to predict cancer progression. Results are presented as median and interquartile range (median (IQR₁; IQR₃)). These two cut-off values were then used to evaluate the association between DFS and circulating fibrocytes or density of tissular distal fibrocytes.

Among the 35 patients included, 46% were males, 30% current smokers and 34% suffered from COPD. Mean±sD age was 64.8±13.2 years. Histology of resected lung cancer was for 23 (66%) adenocarcinoma, five (14%) squamous cell carcinoma and seven (20%) other histology. 22 (63%), 10 (28%) and three (9%) were, respectively, pT1, pT2 and pT3 according to the 7th TNM classification, all being R0. Follow-up duration and DFS were 1902 (1581; 2316) and 1516 (995; 1780) days, respectively. The median percentage of circulating fibrocytes among PBMC was 6.2% (2.1%; 11.6%).

The median density of peri-bronchial fibrocytes was 9.0 (3.6; 29.4)×10⁶ cells·m⁻² and the median density of intra-tumoral fibrocytes was 2.0 (1.5; 3.9)×10⁶ cells·m⁻². Among the 35 patients, 35% encountered progression of the disease. Comparison between non-progressors and progressors after follow-up did not show any significant difference in demographic characteristics but revealed a significant difference in circulating fibrocyte percentages (7.4 *versus* 3.5%, respectively; p=0.01). Using ROC analyses to predict progressive status according to circulating fibrocytes, the area under the curve (AUC) was 0.75 (p=0.01) with an optimal cut-off of 6% for a sensitivity of 75% and a specificity of 70% (figure 1a). We used this




FIGURE 1 Circulating and peri-bronchial fibrocytes are able to significantly predict longer disease-free survival (DFS). a) Receiver operating characteristic (ROC) curve analysis for circulating fibrocytes. The arrow represents the optimal circulating fibrocytes threshold (*i.e.* 6% of peripheral blood mononuclear cells (PBMCs)), with a sensitivity of 75% and a specificity of 70%. b) Kaplan–Meier survival curve according to the threshold of 6% of PBMC for circulating fibrocytes. Survival is significantly different between the two groups (p=0.01). c) ROC analysis for peri-bronchial fibrocytes. The arrow represents the optimal peri-bronchial fibrocyte threshold (*i.e.* 5.8×10^6 cells·m⁻²), with a sensitivity of 61% and a specificity of 74%. d) Kaplan–Meier survival curve according to the peri-bronchial fibrocyte threshold of 5.8×10^6 cells·m⁻². Survival is significantly different between the two groups (p=0.03). AUC: area under the curve.

cut-off to divide patients into two groups. Patient characteristics were not significantly different between the two groups. By contrast, patients with a percentage of circulating fibrocytes below 6% had a significantly shorter DFS (1107 *versus* 1626 days; p<0.0001) (figure 1b). Not surprisingly, as circulating fibrocyte percentage is positively correlated with peri-bronchial fibrocyte density (Spearman; p<0.001, rho=0.7) [14], we observed a similar significant relationship for tissue fibrocyte density (p=0.03) (figure 1c and d). Similarly, intra-tumoral fibrocytes were also significantly higher among non-progressors (2.3 *versus* 1.6×10^6 cells·m⁻²; p=0.03). Of note, the observed effect seemed to be specific to fibrocytes and not related to COPD, as a similar proportion of COPD patients was observed in both groups (five (30%) *versus* seven (35%); p=0.46).

Recurrence after surgery remains unacceptably high, even for patients with stage I disease in whom neither nodal nor other metastatic involvement was detected at the time of surgery. This is the first study showing a link between circulating fibrocytes and prognosis in the early stage of lung cancer after surgery with a long-term follow-up. Identifying a new biomarker is a major issue, so that patient care can be adapted and/ or treatment modulated, in order to avoid recurrence. Indeed, early detection and relapse from lung cancer prediction is of major interest for both patients and healthcare professionals to better manage costs, treatment intensity and time spent around medical care. Although some progress has been made on the early prognosis of cancer, further studies are required to identify biomarkers that are suitable for medical use in the clinical setting in order to estimate progression. Ultimately, predicting the exact survival period after diagnosis increases the prognostic accuracy and might lead to better informed decision-making both for the patient and in terms of the physician's efforts.

With regard to the mechanism, current literature indicates a detrimental role for fibrocytes in the tumour microenvironment. However, we observed here that a higher proportion of circulating and intra-tumoral fibrocytes was associated with a better prognosis. As fibrocytes are able to remodel the extracellular matrix by collagen secretion or endocytosis [15], or even *via* extracellular vesicle secretion [16], such microenvironmental tissue remodelling may prevent metastatic cell dissemination. Moreover, recent data pointed out the beneficial role of fibrocytes in lung cancer: by a direct interaction with CD8⁺ cytotoxic T cells *via* CD86/CD28 co-stimulation, fibrocytes have been shown to promote CD8⁺ T cell proliferation and act synergically with PD-L1/PD-1 blockade [17]. However, we did not find any association between the number of intra-tumoral CD8T cells and progression. Fibrocytes could play a role, not directly in the microenvironment of the tumour, but in micrometastasis genesis. Overall, they could reduce metastatic risk by stimulating anti-tumoral auto-immunity. However, due to some limitations, such as the absence of a validation cohort and the small number of patients, further studies are still required to clarify the mechanism linking fibrocytes and lung cancer survival.

In conclusion, circulating fibrocytes could act as an additional tool to identify patients who will suffer from a worse-than-expected prognosis after surgery for early-stage lung cancer, since a lower concentration of circulating fibrocytes was associated with a shorter disease-free survival.

```
Pauline Henrot <sup>1,2,3,4</sup>, Fabien Beaufils<sup>1,2,3,4</sup>, Matthieu Thumerel <sup>1,2,3,4</sup>, Edmée Eyraud<sup>1,2</sup>, Augustin Boudoussier<sup>3</sup>, Hugues Begueret<sup>3</sup>, Elise Maurat<sup>1,2</sup>, Pierre-Olivier Girodet<sup>1,2,3</sup>, Roger Marthan<sup>1,2,3</sup>, Patrick Berger <sup>1,2,3</sup>, Isabelle Dupin <sup>1,2</sup> and Maéva Zysman<sup>1,2,3</sup>
```

¹Univ-Bordeaux, Centre de Recherche Cardio-thoracique de Bordeaux, INSERM U1045, Pessac, France. ²Inserm, Centre de Recherche Cardio-thoracique de Bordeaux, U 1045 & CIC 1401, Pessac, France. ³CHU de Bordeaux, Hôpital du Haut-Lévêque, Services des Maladies Respiratoires, Explorations Fonctionnelles Respiratoires, Anatomopathologie & Chirurgie Thoracique, Pessac, France. ⁴Co-first authors.

Corresponding author: Maéva Zysman (maeva.zysman@chu-bordeaux.fr)

This study is registered at Clinicaltrials.gov as NCT01692444. The individual datasets after deidentification used and analysed during the current study are available from the corresponding author on reasonable request.

Conflict of interest: P. Henrot reports non-financial support from Avad, outside the submitted work. F. Beaufils reports personal fees and non-financial support from Novartis, Chiesi and AstraZeneca, outside the submitted work. M. Thumerel has nothing to disclose. E. Eyraud has nothing to disclose. A. Boudoussier has nothing to disclose. H. Begueret has nothing to disclose. E. Maurat has nothing to disclose. P-O. Girodet reports grants,

personal fees and non-financial support from AstraZeneca, personal fees and non-financial support from Chiesi, GlaxoSmithKline, Novartis and Sanofi, outside the submitted work. R. Marthan has nothing to disclose. P. Berger reports grants, personal fees and non-financial support from AstraZeneca, personal fees and non-financial support from Chiesi, GlaxoSmithKline, Novartis and Sanofi, outside the submitted work. I. Dupin reports grants from Fondation Bordeaux Université, during the conduct of the study; and has a patent (EP number 15152886.6, *i.e.* new compositions and methods of treating and/or preventing chronic obstructive pulmonary disease) pending. M. Zysman reports grants and personal fees from AstraZeneca, personal fees from GSK, Boehringer Ingelheim, CSL Behring and Chiesi, outside the submitted work.

References

- 1 Bray F, Ferlay J, Soerjomataram I, *et al.* Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; 68: 394–424.
- 2 Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest 2009; 136: 260–271.
- **3** Pepek JM, Chino JP, Marks LB, *et al.* How well does the new lung cancer staging system predict for local/ regional recurrence after surgery? A comparison of the TNM 6 and 7 systems. *J Thorac Oncol* 2011; 6: 757–761.
- 4 Martucci N, Morabito A, La Rocca A, et al. Surgery in small-cell lung cancer. Cancers (Basel) 2021; 13: 390.
- 5 Martini N, Burt ME, Bains MS, *et al.* Survival after resection of stage II non-small cell lung cancer. *Ann Thorac Surg* 1992; 54: 460–465.
- 6 Martini N, Bains MS, Burt ME, *et al.* Incidence of local recurrence and second primary tumors in resected stage I lung cancer. *J Thorac Cardiovasc Surg* 1995; 109: 120–129.
- 7 Cruz C, Afonso M, Oliveiros B, *et al.* Recurrence and risk factors for relapse in patients with non-small cell lung cancer treated by surgery with curative intent. *Oncology* 2017; 92: 347–352.
- 8 Hung J-J, Yeh Y-C, Jeng W-J, *et al.* Prognostic factors of survival after recurrence in patients with resected lung adenocarcinoma. *J Thorac Oncol* 2015; 10: 1328–1336.
- 9 Bucala R, Spiegel LA, Chesney J, *et al.* Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. *Mol Med* 1994; 1: 71–81.
- 10 Moeller A, Gilpin SE, Ask K, *et al.* Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2009; 179: 588–594.
- 11 Stewart ID, Nanji H, Figueredo G, *et al.* Circulating fibrocytes are not disease-specific prognosticators in idiopathic pulmonary fibrosis. *Eur Respir J* 2021; 58: 2100172.
- 12 van Deventer HW, Palmieri DA, Wu QP, *et al.* Circulating fibrocytes prepare the lung for cancer metastasis by recruiting Ly-6C+ monocytes *via* CCL2. *J Immunol* 2013; 190: 4861–4867.
- **13** Mitsuhashi A, Goto H, Saijo A, *et al.* Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab. *Nat Commun* 2015; 6: 8792.
- 14 Dupin I, Thumerel M, Maurat E, *et al.* Fibrocyte accumulation in the airway walls of COPD patients. *Eur Respir* J 2019; 54: 1802173.
- **15** Bianchetti L, Barczyk M, Cardoso J, *et al.* Extracellular matrix remodelling properties of human fibrocytes. *J Cell Mol Med* 2012; 16: 483–495.
- **16** Sato S, Chong SG, Upagupta C, *et al.* Fibrotic extracellular matrix induces release of extracellular vesicles with pro-fibrotic miRNA from fibrocytes. *Thorax* 2021; 76: 851.
- 17 Afroj T, Mitsuhashi A, Ogino H, et al. Blockade of PD-1/PD-L1 pathway enhances the antigen-presenting capacity of fibrocytes. J Immunol 2021; 206: 1204–1214.